EA200970044A1 - Производные пирролидина, обладающие активностью в отношении транспортера glyt1 - Google Patents

Производные пирролидина, обладающие активностью в отношении транспортера glyt1

Info

Publication number
EA200970044A1
EA200970044A1 EA200970044A EA200970044A EA200970044A1 EA 200970044 A1 EA200970044 A1 EA 200970044A1 EA 200970044 A EA200970044 A EA 200970044A EA 200970044 A EA200970044 A EA 200970044A EA 200970044 A1 EA200970044 A1 EA 200970044A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glyt1
activity against
pyrrolidine derivatives
napisilate
benzamide
Prior art date
Application number
EA200970044A
Other languages
English (en)
Inventor
Клер Луиз Андертон
Дэвид Клапхэм
Тревор Рэймонд Кил
Леанда Джейн Киндон
Original Assignee
Глэксо Груп Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глэксо Груп Лимитед filed Critical Глэксо Груп Лимитед
Publication of EA200970044A1 publication Critical patent/EA200970044A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Описаны сукцинатные и нападисилатные соли и сольваты 2-(метилокси)-N-[2-метил-1-фенил-2-(1-пирролидинил)пропил]-4,6-бис(трифторметил)бензамида, нападисилат 6-бис(трифторметил)бензамида и их применение при лечении расстройств, относящихся к транспортеру GlyT1, таких как шизофрения.
EA200970044A 2006-06-22 2007-06-20 Производные пирролидина, обладающие активностью в отношении транспортера glyt1 EA200970044A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0612420.0A GB0612420D0 (en) 2006-06-22 2006-06-22 Compounds
PCT/EP2007/056106 WO2007147831A1 (en) 2006-06-22 2007-06-20 Pyrrolidine derivatives having activity at the glyt1 transporter

Publications (1)

Publication Number Publication Date
EA200970044A1 true EA200970044A1 (ru) 2009-04-28

Family

ID=36803732

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970044A EA200970044A1 (ru) 2006-06-22 2007-06-20 Производные пирролидина, обладающие активностью в отношении транспортера glyt1

Country Status (23)

Country Link
US (1) US20080070973A1 (ru)
EP (1) EP2041082B1 (ru)
JP (1) JP2009541261A (ru)
KR (1) KR20090019847A (ru)
CN (1) CN101506156A (ru)
AR (1) AR061554A1 (ru)
AT (1) ATE444288T1 (ru)
AU (1) AU2007263058A1 (ru)
BR (1) BRPI0713311A2 (ru)
CA (1) CA2655399A1 (ru)
CL (1) CL2007001808A1 (ru)
CR (1) CR10498A (ru)
DE (1) DE602007002642D1 (ru)
EA (1) EA200970044A1 (ru)
ES (1) ES2333918T3 (ru)
GB (1) GB0612420D0 (ru)
IL (1) IL195633A0 (ru)
MA (1) MA30522B1 (ru)
NO (1) NO20085412L (ru)
PE (1) PE20080380A1 (ru)
TW (1) TW200817322A (ru)
WO (1) WO2007147831A1 (ru)
ZA (1) ZA200810009B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20061156A1 (es) 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina
JP2010530397A (ja) * 2007-06-20 2010-09-09 グラクソ グループ リミテッド アミド形成の改善方法
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
ES2928785T3 (es) 2017-10-13 2022-11-22 Treeway Tw001 B V Sal de edaravona

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2746959A (en) * 1953-06-02 1956-05-22 American Home Prod Diphenylethylenediamine-penicillin salt
US3145209A (en) * 1961-07-31 1964-08-18 Olin Mathieson Substituted aminophenyl-ethylamine derivatives
NZ237443A (en) * 1990-04-10 1993-11-25 Asta Medica Ag Phenalkylethylenediamine and aminomethyltetra hydroisoquinoline derivatives, platinum (ii) and (iv) complexes, methods of preparation and pharmaceutical compositions
GB0130696D0 (en) * 2001-12-21 2002-02-06 Smithkline Beecham Plc Chemical Compounds
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
PE20061156A1 (es) * 2004-12-23 2006-12-16 Glaxo Group Ltd Derivados de benzamida como agentes inhibidores del transportador de glicina

Also Published As

Publication number Publication date
CL2007001808A1 (es) 2008-01-18
DE602007002642D1 (de) 2009-11-12
IL195633A0 (en) 2009-09-01
ES2333918T3 (es) 2010-03-02
PE20080380A1 (es) 2008-05-31
AR061554A1 (es) 2008-09-03
BRPI0713311A2 (pt) 2012-03-06
NO20085412L (no) 2009-01-22
CA2655399A1 (en) 2007-12-27
WO2007147831A1 (en) 2007-12-27
EP2041082A1 (en) 2009-04-01
EP2041082B1 (en) 2009-09-30
AU2007263058A1 (en) 2007-12-27
TW200817322A (en) 2008-04-16
GB0612420D0 (en) 2006-08-02
ATE444288T1 (de) 2009-10-15
JP2009541261A (ja) 2009-11-26
CN101506156A (zh) 2009-08-12
KR20090019847A (ko) 2009-02-25
CR10498A (es) 2009-03-20
US20080070973A1 (en) 2008-03-20
ZA200810009B (en) 2009-11-25
MA30522B1 (fr) 2009-06-01

Similar Documents

Publication Publication Date Title
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
EA200801551A1 (ru) Применение сульфонамидных производных в лечении расстройств метаболизма и нервной системы
EA200802054A1 (ru) Ингибиторы фермента
EA201200653A1 (ru) Гетариламинохинолины
ATE447559T1 (de) 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3- carboxamid derivate als mek inhibitoren zur behandlung von hyperproliferativen erkrankungen
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
DK1776349T3 (da) 2-amino-puinazolin derivater anvendelige som inhibitorer af beta-sekretase (BACE)
EA200870446A1 (ru) Пиридон сульфонамиды и пиридон сульфамиды в качестве ингибиторов мек
ATE516286T1 (de) 5-(ä1,3,4üoxadiazol-2-yl)-1h-indazol und 5-(ä1,3, 4üthiadiazol-2-yl)-1h-indazol derivate als sgk- inhibitoren zur behandlung von diabetes
EA200870360A1 (ru) Бензимидазолы, обладающие активностью в отношении рецепторов м1, и их применение в медицине
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
EA200801897A1 (ru) Ингибиторы mnk2 на основе 8-гетероарилпурина для лечения метаболических нарушений
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
ATE471326T1 (de) Substituierte thienopyrrolcarbonsäureamide, pyrrolothiazolcarbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
EA200600203A1 (ru) Производные 2-(хиноксалин-5-илсульфониламино)бензамида в качестве модуляторов сск2
EA201000562A1 (ru) Производные n-(пиразол-3-ил)бензамида в качестве активаторов глюкокиназы
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
DK1919466T3 (da) Formuleringer til behandling af lipoprotein-abnormiteter omfattende et statin og et methylnicotinamidderivat
DE602006014305D1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
EA201201170A1 (ru) Гетариламинонафтиридины
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3
ATE396970T1 (de) 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri